Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ibuzatrelvir

Small molecule · Inhibitor of SARS-CoV-2 main protease (Mpro; 3C-like protease; nsp5) · developed by Pfizer

Phase 3 Most advanced trial
PFE Developer

What is Ibuzatrelvir?

Ibuzatrelvir is an orally bioavailable inhibitor of the SARS-CoV-2 main protease (Mpro, also called 3C-like protease). It reversibly binds the catalytic cysteine Cys145, blocking cleavage of viral polyproteins needed for viral replication. It is studied in COVID-19 and SARS-CoV-2 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PF-07817883
Drug type
Small molecule
Targets
SARS-CoV-2 main protease (Mpro; 3C-like protease; nsp5)
Mechanism
Inhibitor of SARS-CoV-2 main protease (Mpro; 3C-like protease; nsp5)
Pathways
viral polyprotein processing, viral transcription and replication
Therapy area
Infectious disease
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
KZ2X7QH2VT

Conditions studied

COVID-19 SARS-CoV-2 Infection

More from Pfizer

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Ibuzatrelvir

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.